COX2 inhibitors for acquired brain injuries: is the time ripe?
Strauss
Kenneth I
KI
D000818:Animals; D000831:Animals, Newborn; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D051546:Cyclooxygenase 2 / Q000096:biosynthesis; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000517:prevention & control*; D007249:Inflammation / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D009578:Nitrobenzenes / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*
D052246:Cyclooxygenase 2 Inhibitors; D018696:Neuroprotective Agents; D009578:Nitrobenzenes; D013449:Sulfonamides; C080955:N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide; D051546:Cyclooxygenase 2